⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21848961 | 0.82 | PDE4A (0.31) | — | |
| SCHEMBL18861598 | 0.82 | — | — | |
| SCHEMBL20462582 | 0.82 | — | — | |
| SCHEMBL2611135 | 0.73 | LRRK2 (0.32) | — | |
| SCHEMBL21599322 | 0.71 | DGAT1 (0.31) | — | |
| SCHEMBL22530446 | 0.71 | — | — | |
| SCHEMBL21720098 | 0.71 | — | — | |
| SCHEMBL6020795 | 0.71 | — | — | |
| SCHEMBL22859931 | 0.71 | — | — | |
| SCHEMBL21721158 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160304500-A1 | Methods of Promoting Wound Healing Using CRM1 Inhibitors | Karyopharm Therapeutics Inc. | 2016-10-20 | — | — | US | disclosed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
| US-8710079-B2 | Quinoline compounds and their use for treating viral infection | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2014-04-29 | — | — | US | disclosed |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20110263620-A1 | QUINOLINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-10-27 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080051441-A1 | Aryl Sulphonamide Modulators | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |